logo-loader
viewAllergy Therapeutics PLC

Allergy Therapeutics boss says the firm is outperforming its competitors

Chief executive of Allergy Therapeutics (LON:AGY), Manuel Llobet, said maintaining double digit growth in the first half for consecutive years “demonstrates our robust business model.”

“We are outperforming our competitors and we are taking market share,” he added, as the firm gave an upbeat assessment of current trading.

It expects revenues to be in the order of £31.5mln in the first half of its financial year, which equates to a 12% rise at constant currencies.

Quick facts: Allergy Therapeutics PLC

Price: 11.9 GBX

AIM:AGY
Market: AIM
Market Cap: £75.7 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Allergy Therapeutics PLC named herein, including the promotion by the Company of Allergy Therapeutics PLC in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Allergy Therapeutics confident on the coming year as it reports 8% boost to...

Allergy Therapeutics PLC's (LON:AGY) Manuel Llobet and Nick Wykeman talk Proactive London's through the firm's preliminary results to June 2019. The vaccines specialist posted an 8% boost to revenues on a constant currencies basis to £73.7mln, giving ‘pre-R&D’ operating earnings of...

on 25/9/19

2 min read